BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation
Following dissapointing results from the phase IIb study, Stayble Therapeutics is shifting its focus to the phase Ib study in hearniated disc patients. At the same time, the company plans to reduce costs in order to complete the study without additional funding. CEO Andreas Gerward shares more details in an interview with BioStock.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se